Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06895928
PHASE2

A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors

Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with other antitumor therapies in advanced solid tumors to explore the reasonable dosage, safety and efficacy of SHR-A2102 for advanced solid tumors.

Official title: A Phase II, Multicenter, Open-Label Study of Safety, Tolerability and Efficacy of SHR-A2102 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

400

Start Date

2025-03-28

Completion Date

2028-12

Last Updated

2025-04-22

Healthy Volunteers

No

Interventions

DRUG

SHR-A2102

SHR-A2102 for injection.

DRUG

Bevacizumab Injection

Bevacizumab injection.

DRUG

Adebelimab Injection

Adebelimab injection.

DRUG

Ametinib Mesylate Tablets

Ametinib mesylate tablets.

DRUG

Osimertinib Mesylate Tablets

Osimertinib mesylate tablets.

Locations (1)

Shanxi Cancer hospital

Taiyuan, Shanxi, China